3种核苷类似物治疗慢性乙型肝炎的成本-效果分析

林惊世; 林惊世

[1]

Rehermann B,Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infextion[J]. Nat Rev lmmunol,2005,5(3):215.

[2]

Lu FM, Zhuang H. Management of hepatitis B in China[J].Chin Med J, 2009,122(1): 3.

[3]

Choe WH, Hong SP, Kim BK, et al.Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir[J].Antivir Ther. 2009, 14(7):985.

[4]

中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881.

[5]

陈洁. 药物经济学[M]. 第3版. 成都:成都科技大学出版社,2000:97.

[6]

艾伟鹏,方红成. 三种他汀类药物治疗高脂血症的经济学分析[J].现代医药卫生,2005,21(10):1200.

[7]

孔晓东.药物经济学:概念、方法和应用[J].国外医学药学分册,1994,21(1):16.

[8]

Lok ASF,McMahon BJ. AASLD practice guidelines: Chronic hepatitis B[J]. Hepatology,2007,45(2):507.

[9]

Chang TT, Jia JD, Omata M,et al. New therapies for chronic hepatitis B infection[J]. Liver International,2006 26(suppl2):30.

[10]

Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B[J]. Ther Clin Risk Manag,2009,5(10):789.